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ABSTRACT 
Insulin resistance and metabolic dysfunction in the brain are considered to be the 
pathophysiological core of sporadic Alzheimer’s disease (sAD). In line with that fact, 
nutrients that could have therapeutic effects at this level have been investigated as possible 
targets in AD therapy. Galactose, an epimer of glucose, may serve as an alternative source of 
energy, and given orally may stimulate secretion of the incretin hormone glucagon-like 
peptide-1 (GLP-1). Our preliminary research indicated that oral galactose might prevent 
development of memory impairment in a rat model of sAD generated by 
intracerebroventricular administration of streptozotocin (STZ-icv). Here, we explored whether 
chronic oral galactose treatment could have beneficial effects on cognitive deficits already 
manifested at the time of initiation of galactose treatment in adult STZ-icv rats (treatment 
initiated 1 month after STZ-icv injection). The results clearly show that a 2-month exposure to 
oral galactose (200 mg/kg/day administered in a drink ad libitum) normalises impaired 
learning and memory functions. Memory improvement was accompanied by an improvement 
in brain glucose hypometabolism measured by 18fluorodeoxyglucose-positron emission 
tomography neuroimaging and by increments in active GLP-1 plasma levels as well as by an 
increased expression of GLP-1 receptors in the hippocampus and hypothalamus. Our findings 
provide strong evidence of beneficial effects of oral galactose treatment in the STZ-icv rat 
model of sAD and present possible underlying mechanisms including both direct effects of 
galactose within the brain and indirect GLP-1-induced neuroprotective effects that might open 
a new, dietary-based strategy in sAD treatment. 
KEYWORDS 
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1. INTRODUCTION 
Sporadic Alzheimer disease (sAD) is the most frequent human neurodegenerative disorder 
associated with progressive loss of cognitive function [1]. Recent studies proposed sAD to be 
a central insulin-resistant state[2–5] accompanied by brain glucose hypometabolism already 
seen in the early stages of the disease [6], [7], [8], [9]. Using 18fluorodeoxyglucose (FDG) 
positron emission tomography (PET) measurements of regional cerebral metabolic rates for 
glucose (CMRgl), a significant relationship was detected between higher disease severity and 
lower CMRgl in regions associated with learning and memory [10]. Insulin resistance has 
been considered as one of the factors that could be involved in the reduction of CMRgl [11, 
12, 13].  The causes of brain glucose hypometabolism in sAD as well as the development of 
brain insulin resistance are hard to investigate in humans during life and particularly in the 
preclinical phase of sAD, which is why representative animal models are needed.  
Modelling of brain insulin resistance is performed by intracerebroventricular (icv) 
administration of streptozotocin (STZ; 2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-
glucopyranose) in rat and mouse [16, 17, 18, 19] as well as in monkey [20, 21]. STZ is a 
substance selectively toxic for insulin-secreting/producing cells [20, 21] and its icv 
application also induces cholinergic deficits [22], oxidative stress [23], neuroinflammation 
[24, 25] and a reduction in cortical and hippocampal glucose/energy metabolism [20, 26, 28, 
29, 30], followed by progressive deficits in learning and memory in rats and mice [13, 30]. 
Other sAD-like features in the STZ-icv model are synaptic loss and neuronal damage as well 
as pathological amyloid β 1-42 (Aβ1-42) and tau accumulation [14, 31, 32]. Based on all 
these findings, the STZ-icv model is considered to be a representative non-transgenic model 
for sAD [5, 16, 19, 33]. 
The STZ-icv model has also been widely used as a platform for testing the therapeutic 
potential of different compounds [33]. There is an urgent need for novel anti-AD therapeutic 
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strategies that can prevent, slow down or stop the progression of neurodegeneration and 
dementia [34, 35]. Our preliminary research demonstrated that a 1-month daily treatment with 
oral galactose (200 mg/kg) that was initiated immediately after the STZ-icv injection 
prevented STZ-icv-induced learning and memory deficits [36].  
The exact mechanism by which orally given galactose affects the cognition is still unknown.  
As a C-4 epimer of glucose, galactose could serve as an alternative source of energy to the 
brain following its conversion to glucose in the Leloir pathway [37, 38]. Since galactose 
enters the cell via insulin-independent glucose transporter GLUT3 [39, 40], in the condition of 
glucose hypometabolism and insulin resistance in the brain such a galactose-induced and 
insulin-independent increment in intracellular glucose level might compensate for the reduced 
glucose and energy metabolism in the brain. To test this hypothesis, in this study we measured 
glucose metabolism in the brain by FDG-PET in a STZ-icv rat model following chronic oral 
galactose treatment.  
Another factor that could account for the beneficial effects of oral galactose is the stimulation 
of glucagon-like peptide-1 (GLP-1) secretion [41] induced by oral (but not parenteral) 
galactose administration. GLP-1 is an incretin hormone secreted from the intestinal L-cells in 
response to food, which  increases glucose-stimulated pancreatic insulin release [42], [43]. 
GLP-1 also acts as a neuropeptide in the brain where it has a neuroprotective and neurotrophic 
effect [44, 45] and can promote neurogenesis [44, 46]. Treatment with GLP-1 analogues was 
found to significantly improve learning and memory in a STZ-icv rat model [47]. GLP-1 can 
also be produced centrally in the nucleus of the solitary tract [43], from which proglucagon 
neurons project to the hypothalamus and hippocampus [41]. GLP-1 binds to and activates its 
receptor (GLP-1R), the expression of which is also found in the brain, especially in the 
hypothalamus and hippocampus [48], [49]. This study explored whether oral galactose 
treatment alters GLP-1 and insulin levels in the blood and cerebrospinal fluid (CSF), as well 
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as the expression of GLP-1R in the brain of STZ-icv-treated rats. Metabolic parameters, as 
well as associated learning and memory functions, were measured after two months of oral 
galactose treatment which was initiated when cognitive deficits were already manifested in 
the STZ-icv rat model of sAD. 
2. MATERIAL AND METHODS 
2.1. Animals 
Adult (3-month old) male Wistar rats weighing 270-370 g (University of Zagreb, School of 
Medicine, Department of Pharmacology) were used in all experiments. The animals were kept 
on standardised food pellets and water ad libitum, in a room with a 12-h light/12-h dark cycle, 
at a constant temperature (21-23°C) and humidity (40-70%). The animals were group-housed 
(2-3 per cage) after icv administration of STZ or citrate buffer (controls). During the chronic 
oral galactose treatment the animals were taken from the grouped cages and placed in 
individual cages, with a single bottle per animal, each day from 4 p.m. overnight to 8 a.m. the 
following day, after which they were returned to their previous grouped cages.  
2.2. Materials 
Streptozotocin (STZ), D-galactose, protease inhibitor cocktail, PhosStop phosphatase 
inhibitor tablets and DPP-IV inhibitor were acquired from Sigma-Aldrich Chemie (Munich, 
Germany). The glucose measuring kit (Greiner Diagnostic Glucose GOD-PAD-PAP) was 
acquired from Dijagnostika (Sisak, Croatia). The Amplex Red Galactose/Galactose Oxidase 
Kit was purchased from Invitrogen (Eugene, OR, USA). The ELISA Kits for rat/mouse 
insulin, active GLP-1 and total GLP-1 were acquired from Merck Millipore (Billerica, USA). 
The following antibodies were used: anti-GLP-1R / Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), monoclonal anti-β-actin / Sigma-Aldrich (St. Louis, Missouri, USA) as well as 
anti-mouse IgG horseradish peroxidase-linked antibody and anti-rabbit IgG horseradish 
peroxidase-linked antibody acquired from CellSignaling (Beverly, MA, USA). The 
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chemiluminescent Western blot detection kit (SuperSignal West Femto Chemiluminescent 
Substrate) was acquired from Thermo Scientific (Rockford, IL, USA). The Anti-Rabbit IgG 
(H+L) Secondary Antibody, Alexa Fluor 555 was acquired from Thermo Fisher Scientific 
(Waltham, MA, USA) and donkey serum from Sigma-Aldrich Chemie (Munich, Germany). 
Colourimetric and fluorimetric measurements were performed on an Infinite F200 PRO 
multimodal microplate reader (Tecan, Switzerland). 
2.3. Drug treatments 
Streptozotocin (STZ) treatment. The rats were subjected to general anaesthesia (ket 
amine 50 mg/kg/xylazine 5 mg/kg ip) and given STZ bilaterally into each lateral ventricle (2 
µL/ventricle) in a total dose of 3 mg/kg (dissolved in 0.05 M citrate buffer, pH 4.5, split in 
two doses on day 1 and 3), according to the procedure first described by Noble et al. [50] and 
used afterwards in our experiments [5, 15, 32, 51]. The control animals received an equal 
volume of vehicle icv (0.05 M citrate buffer, pH 4.5) by the same procedure. 
Galactose treatment. Single oral doses (200 mg/kg dissolved in 1 ml of water /6%/) given via 
gastric tube and single intraperitoneal (ip) doses (200 mg/kg dissolved in 1 ml saline /6%/ ) 
were both administered at the required concentrations adjusted according to the rats’ body 
weight in a volume of 1 mL per rat, in order to explore the effect of single galactose dose on 
GLP-1, insulin, glucose and galactose levels in the plasma and cerebrospinal fluid (CSF) of 
non-anaesthetised animals. Two-month oral administration of galactose (200 mg/kg/day) 
dissolved in tap water was given as a drink ad libitum (final daily administration of 20 mL 
galactose solution per rat placed alone in a cage, corresponding to 0.3% galactose solution; 
the required concentration was adjusted to the rat body weight, measured on a weekly basis). 
The respective controls (placed in individual cages from 4 p.m. overnight to 8 a.m. the 
following day) received equal amounts of tap water for drinking in similar bottles. A daily 
water intake of 20 mL per rat was chosen based on previous observations [36], and a titration 
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period during the first 5 days when the volumes of 10 to 25 mL of galactose solution were put 
in the bottle and the retained amount checked the following morning. After smaller volumes 
of galactose solution the animals appeared thirsty on the following morning, whereas with 
large volumes small amounts remained in the bottle, which were then given by oral gastric 
tube to assure that all animals received the desired daily galactose dose. The volume of 20 mL 
per rat was found to be optimal, with no remnants of liquid in the bottles and no thirst in the 
animals. After checking that no galactose solution was retained in the bottles in the morning 
(solution remnants were not found with the volume of 20 mL), the animals were placed back 
and kept group-housed (2-3 per cage), supplied with tap water bottles until 4 p.m. in the  
afternoon. 
2.4. Experimental design  
1) Assessment and comparison of the effects of a single galactose dose given orally and 
peritoneally in STZ-icv pretreated rats (1 month before galactose load). The animals were 
divided into 4 groups (10 animals per group): CTR, control group (vehicle-icv treated); STZ, 
STZ-icv group; STZ+200 po GAL, STZ-icv group treated with 1x200 mg/kg galactose po 
(gastric tube); STZ+200 ip GAL, STZ-icv group treated with 1x200 mg/kg galactose ip. A 
time-point of 15 minutes after galactose load was chosen for blood/CSF measurements based 
on literature data of rapid conversion of galactose to glucose in the blood measured by (C14)-
detection 15 minutes after 14C-galactose-oral ingestion in rats [52]. The rats were 
anaesthetised using thiopental 50 mg/kg/diazepam 5 mg/kg ip; blood samples were taken 
from the retro-orbital sinus and CSF samples from the cistern magna. DPP-IV inhibitor 
(1:100) was added immediately to each retrieved sample and the blood was centrifuged for 10 
minutes at 3600 rpm. Afterwards, the animals were decapitated, the brains quickly removed, 
and the hippocampus dissected out, frozen in liquid nitrogen, and stored at -80ºC. Cognitive 
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deficits in STZ-icv rats were confirmed before single galactose load by Passive Avoidance 
(PA) test. 
2) Determination of possible therapeutic effects of 2-month oral galactose treatment (drink) 
on cognitive deficits and brain glucose hypometabolism in rats pretreated with STZ-icv 1 
month before galactose treatment initiation. The animals were divided into 4 groups (10 
animals per group): CTR, control group (vehicle-icv treated); STZ, STZ-icv group; 
CTR+GAL, control group treated daily with galactose 200 mg/kg po; STZ+GAL, STZ-icv 
group treated daily with galactose 200 mg/kg po. Cognitive performance was assessed by the 
Morris Water Maze Swimming Test (MWM) before the initiation of galactose treatment to 
confirm the presence of cognitive deficits in STZ-icv rats and to equally distribute the animals 
based on their cognitive performance. After the completion of galactose treatment, cognitive 
performance was assessed by the MWM and PA tests. Following cognitive testing and FDG-
PET scan and blood/CSF sample retrieval, 6 animals per group were euthanised in general 
anaesthesia (thiopental 50 mg/kg / diazepam 5 mg/kg ip) followed by decapitation; the brains 
were quickly removed and the hippocampus dissected out, frozen in liquid nitrogen and stored 
at -80ºC. The remaining 4 animals per group were also subjected to deep anaesthesia 
(thiopental 50 mg/kg / diazepam 5 mg/kg ip) and then transcardially perfused with 250 mL of 
saline followed by 250 mL of 4% paraformaldehyde, pH 7.4. The brains were quickly 
removed and cryoprotected with sucrose (through series of sucrose 15% and 30%) and then 
stored at -80°C for further histology analysis.  
The galactose dose of 200 mg/kg was chosen based on the results of our preliminary research 
demonstrating that this dose successfully prevented the development of cognitive deficits in 
the STZ-icv rat model [36]. 
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2.5. Cognitive testing 
Morris Water Maze Swimming Test (MWM). The procedure of MWM [53, 54] consisted of 
5-day learning and memory training trials, and a probe trial on day 6, all performed in a 180- 
cm-diameter round pool, 60 cm deep, with water temperature set at 25±1oC. On days 1-5, the 
rats were trained to escape the water by finding a hidden glass platform (15-cm diameter) 
submerged about 2 cm below the water surface and placed at the edge of the NorthWest/NW 
quadrant. Staying on the platform in order to memorise its location was allowed for 15 s. Four 
consecutive trials were performed per day, each from a different starting position 
(SouthWest/SW, South/S, East/E and NorthEeast/NE), separated by a 30-min rest period. The 
rats were released into the pool facing its wall. The platform was kept at the same position 
during the training period, but the starting position schedule changed. The escape latency 
(time needed to find the platform after being released into the pool), was recorded during 
training trials which tested the capability of learning memory. A probe trial which tested 
memory retention was performed (from quadrant SouthEast/SE) with the platform removed 
from the pool, where the time spent in search for the platform within the NW quadrant was 
recorded. The cut-off time was 1 min. The rats with preserved spatial memory (controls) were 
supposed to remember that the platform had previously been there, and, consequently, to 
spend a considerable period of time swimming within the NW quadrant. The rats with 
damaged memory were supposed to have diminished memory of the platform being in the 
NW quadrant, and to spend less time in search of the platform within this quadrant, in 
comparison with the control rats. The number of entries into non-target zones (i.e. quadrants 
other than NW where the platform had been located, expressed as “number of mistakes”) and 
velocity (Suppl 1) were recorded in the training and probe trials. The data was recorded by 
camera (Basler AG) and tracked and analysed using EthoVision XT video tracking software 
(Noldus Information Technology). 
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Passive avoidance test (PA). Passive avoidance behaviour was studied with a step-through 
type passive avoidance test (Ugo Basile, Comerio, Italy) utilising the natural preference of 
rats for dark environments [55]. The PA test is a fear-motivated avoidance task where rats 
learn to avoid stepping through a door to an apparently safer but previously punishment-
related dark compartment. The latency to avoid crossing into the punishment compartment 
serves as an index of the ability to avoid, and allows memory to be evaluated. On the test day, 
the animals with no alterations in memory functions (vehicle-icv treated, controls) were 
supposed to remember receiving a foot shock after entering the dark compartment and, 
therefore, to stay in the light compartment longer. The animals with damaged memory were 
supposed to have less memory of the received foot shock in the dark compartment, and thus to 
spend less time in the light compartment and enter the dark area more rapidly in comparison 
with the control rats. The three-day PA test performance started with a habituation day to 
make the rats familiar with the environment (no foot shock, i.e. pre-shock latency), followed 
by a training day in which a foot shock (0.3-0.5 mA, depending on the rat weight, duration 2 
seconds) was delivered, and, lastly, a testing day (without foot shock, i.e. post-shock latency). 
The time required to enter the dark compartment was measured with a cut-off time of 5 min. 
The PA test was performed at the end of the 2-month oral galactose treatment.  
2.6. FDG-PET imaging 
For FDG-PET imaging, the animals were anaesthetised in an induction chamber with 4% 
isoflurane (Forane, Abbott laboratories, UK) in 100% oxygen with a delivery rate of 0.6 
l/min, and intravenously injected with 30 MBq of PET radiotracer [18F]Fluoro-2-deoxy-2-D-
glucose (18FDG). After 30 minutes of uptake time, the animals were anaesthetised in the same 
manner and placed into a ClearPET high-performance small animal PET scanner. The 
performances of the commercial ClearPET scanner were described by Roldan et al [56]. 
During the 30-minute scanning, anaesthesia was maintained with 2% isoflurane in 100% 
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oxygen with a delivery rate of 0.6 l/min. The obtained PET scan images were analysed in 
PMOD software for biomedical analysis. For brain analysis, the template of the rat brain atlas 
available in PMOD software was used. For this study, nine regions (CTX frontal /orbito 
frontal, frontal and medial prefrontal/, CTX parietal /parietal, cingulate, motor, retrosplenial, 
somatosensory and visual/, CTX temporal /auditory, entorhinal and insular/, hippocampus, 
amygdala, hypothalamus, thalamus, brainstem and cerebellum) were selected as regions of 
interest and underwent further analysis. The results were given as FDG activity per tissue 
volume [kBq/cc]. Food and tap water/galactose solution were available to the rats until the 
beginning of anaesthesia and after FDG-PET imaging. 
2.7. Biochemical analysis 
Tissue preparation for Western blot analysis. Fresh frozen hippocampal tissue samples were 
thawed and homogenised with three volumes of lysis buffer containing 10 mM HEPES, 1 
mM EDTA, 100 mM KCl, 1% Triton X-100, pH 7.5, and a protease inhibitor cocktail (1:100). 
The resulting homogenates were centrifuged at 12000 rpm (13700 xg) for 10 min at 4°C and 
the supernatants frozen and stored at -80°C. Protein concentration was measured by the 
Lowry protein assay [57].  
CSF sampling. Withdrawal of CSF was carried out in deeply anaesthetised animals before 
scarification (non-recovery procedure). The animals were subjected to general anaesthesia 
(thiopental 50 mg/kg / diazepam 5 mg/kg ip). The heads were flexed downwards at an angle 
of approximately 45°. A small-gauge needle (29 G) was inserted into the cisterna magna by 
using the occipital bone as a landmark, and CSF was sampled by syringe aspiration until its 
colour changed from transparent to reddish (approximately 200 μL per animal).   
Glucose measurements. Blood/CSF glucose concentration was measured 
spectrophotometrically (by the method first described by Trinder [58]) using a commercial 
kit. The measurement was conducted in strict compliance with the manufacturer’s protocol. 
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Absorbance was measured at 500 nm. The concentration of glucose was expressed in mmol/L 
(mM). 
Galactose measurements. Blood/CSF galactose concentration was measured 
spectrophotometrically using a commercial kit. The measurement was conducted by strictly 
following the manufacturer’s protocol. Absorbance was measured using a microplate reader at 
570 nm. The concentration of galactose was expressed in mmol/L (mM). 
Insulin measurements. Blood/CSF insulin levels were measured using a commercial insulin 
ELISA kit. The measurement was conducted by strictly adhering to the manufacturer’s 
protocol. Absorbance was measured at 450 nm and 590 nm using a microplate reader. The 
concentration of insulin was expressed in ng/mL. 
Total GLP-1 measurements. Blood/CSF levels of total GLP-1 (GLP1 7-36 and 9-36) were 
measured using a commercial ELISA kit. The measurement was conducted in strict 
accordance with the manufacturer’s protocol. Absorbance was measured at 450 nm and 590 
nm using a microplate reader. The concentration of total GLP-1 was expressed in pmol/L 
(pM). 
Active GLP-1 measurements. Active GLP-1 (GLP-1 7-36 and 7-37) levels in blood and CSF 
samples were measured using a commercial ELISA kit. The measurement was conducted by 
strictly following the manufacturer’s protocol. The plate was read on a fluorescence plate 
reader at an excitation/emission wavelength of 355/460 nm. The concentration of active GLP-
1 was expressed in pmol/L (pM). The GLP-1 active ELISA kit quantifies active forms of 
GLP-1 (7-36 amide and 7-37) and does not detect other forms, while the GLP-1 total ELISA 
kit is intended for quantification of both active (7-36) and non-active (9-36; degraded by 
dipeptidyl peptidase IV) forms. 
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Western blot analysis (GLP-1R expression). Equal amounts of total protein in the 
hippocampus (35 µg per sample) were separated by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis using 9% polyacrylamide gels, and transferred to nitrocellulose 
membranes. The nitrocellulose membranes were blocked for 1 h at RT in 5% non-fat milk, 
added to low-salt washing buffer (LSWB) containing 10 mM Tris, 150 mM NaCl, pH 7.5 and 
0.5% Tween 20. The blocked blots were incubated with primary anti-GLP-1R antibody 
(1:500) overnight at 4°C. After incubation, the membranes were washed 3x with LSWB and 
incubated for 1 h at RT with secondary antibody solution (anti-rabbit IgG, 1:2000). After 3x 
washing in LSWB, immunoreactive signals were visualised using a chemiluminescence 
Western blotting detection reagent. The signals were captured and visualized with a 
MicroChemi video camera system (DNR Bio-Imaging Systems). The membranes were 
washed 3x with LSWB, blocked the same way, and incubated overnight with loading control 
β-actin (1:2000) at 4°C. The membranes were then washed and incubated for 1 h at RT with a 
secondary antibody solution (anti-mouse IgG, 1:2000), washed in LSWB, and immunostained 
using a chemiluminescence reagent. The signals were captured and visualised with a 
MicroChemi video camera system.  
Immunohistochemistry. Frozen (previously fixative-perfused) brain samples (4 per group) 
were cut using a cryostat (Leica) into 35-µm sections (6 per animal; AP plane: Bregma -1.20 
mm to -3.12 mm) at -25ºC. The sections were washed 3x with PBS-T buffer (0.025% Triton 
X-100 in PBS), incubated with 200 µL of 10x normal donkey serum for 1 h at RT and 
incubated with primary anti-GLP-1R antibody (1:500, diluted in 1x normal donkey serum) or 
normal donkey serum (negative controls) overnight at 4°C. After incubation, the sections 
were washed 3x with PBS-T and incubated for 2 h at RT in the dark with anti-rabbit IgG 
secondary antibody, Alexa Fluor 555. Finally, the sections were washed 3x with PBS-T and 
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mounted on slides, viewed and analysed using an Olympus BX51 microscope and CellSense 
Dimension software. 
2.8. Ethics 
The animal procedures were in compliance with current institutional (University of Zagreb 
School of Medicine), national (Animal Protection Act, NN135/2006; NN 47/2011) and 
international (Directive 2010/63/EU) guidelines on the use of experimental animals. The 
experiments were approved by the national regulatory body, the Croatian Ministry of 
Agriculture (licence number 525-10/0255-15-5).  
2.9. Statistical Analysis 
Data were expressed as mean ± SEM with the significance of between-group differences in all 
cognitive and biochemical analyses tested by Kruskall-Wallis one-way ANOVA analysis of 
variance, followed by Mann-Whitney U-test, with p<0.05 considered statistically significant 
using GraphPad Prism 5 statistical software. The Morris Water Maze test results (learning 
trials) were analysed by Two-way ANOVA for repeated-measures with Bonferroni post-hoc 
test on ln-transformed data to meet the condition of normality. 
3. THEORY 
The protective role of diet has gained considerable attention in the research of novel AD 
therapeutic strategies, but has been generally focused on diets rich in antioxidants and 
polyunsaturated fatty acids [59, 60]. This study combines two current trends, a nutrient as a 
possible therapeutic agent and brain glucose hypometabolism as the therapeutic target, both 
explored here following the administration of a single agent which might have direct 
(glucose/energy replenishing) and indirect (neuroprotective factor stimulating) effects in the 
STZ-icv rat model of sAD. The hypothesis proposed here complies with the current theories 
that multimodal compounds/drugs which combine more than one mechanism of action and/or 
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have more than one target might be more efficient than single-target drugs in AD treatment 
[34, 61]. It is important to mention that oral galactose might have additional effects, like 
stimulation of the secretion of another incretin, glucose-dependent insulinotropic polypeptide 
(GIP), in the gut [62]. GIP has properties similar to GLP-1 in protecting neurons from toxic 
effects, and reversing the detrimental effects that beta-amyloid fragments have on synaptic 
plasticity [63]. GIP analogues have been shown to facilitate synaptic plasticity and reduce 
plaque load in aged wild-type mice and in a transgenic AD mouse model [64, 65], while a 
dual GLP-1/GIP receptor agonist recently demonstrated a potential neuroprotective effect in a 
STZ-icv rat model [66]. Further research in animal AD models is needed to explore whether 
long-term administration of a nutrient like oral galactose, which acts synergistically on 
different targets, might replace therapy with GLP-1 and GIP agonists or dual GLP-1/GIP 
agonists, or even be more efficient due to its additional glucose-replenishing effects. It should 
also be kept in mind that a nutrient might generally have a more acceptable safety profile than 
a drug. Therefore, knowing the detrimental effects of high galactose levels [67–72], the safety 
profile of oral galactose should be well characterised, taking into account its blood level and 
the appropriate pathophysiological state which might be responsive to such a therapy. 
4. RESULTS  
4.1. Chronic oral galactose treatment improves cognitive deficits previously developed 
after STZ-icv administration in rats 
Three months after STZ-icv administration, cognitive deficits were found in the animals 
which were not subjected to chronic oral galactose treatment as demonstrated by MWM and 
PA tests (Fig. 1). In the MWM training (learning) trials STZ rats needed more time to find the 
hidden platform in comparison with the control vehicle-icv treated rats (CTR), which was 
demonstrated by a significantly longer escape latency (p<0.001 on days 3-5; 133%-140%-
107%) and a higher number of mistakes (p<0.05 on days 2-5; 175%-233%-397%-458%), 
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indicating impaired spatial memory and learning ability (Fig. 1a). The deficits in retention of 
spatial memory were manifested as less time spent in search for the removed platform (-56%, 
p=0.0014) in the MWM probe trial, while no difference was found in the number of mistakes 
between the STZ and CTR groups (Fig. 1b). However, the STZ group demonstrated 
impairment of fear-motivated retention memory in the PA test, manifested as a shorter post-
shock latency (-86%, p=0,0002) in comparison with the CTR rats (Fig. 1c). 
The beneficial effects of 2-month oral galactose treatment on spatial memory in the MWM 
test were demonstrated both in the learning ability and memory retention, but more 
pronounced in the former (Fig. 1a, b). They were manifested as a significantly shorter time to 
find the platform (p<0.05 on day 4/-49%/ and 5/-41%/) and a lesser number of mistakes 
(p<0.01 on day 4/-72%) in STZ+GAL compared to STZ rats in the MWM training trials (Fig 
1a). The tendency of the increment of the time spent in the target quadrant (+40%) in the 
probe trial did not reach statistical significance (p=0.09 vs STZ) in the galactose-treated STZ 
group (Fig. 1b). The velocity of swimming in the MWM learning and probe trials was not 
affected by any of the treatments, as presented in Suppl. 1.  
The beneficial effect of chronic oral galactose treatment in the STZ rats was also 
demonstrated by the fear-conditioned escape memory in the PA test, manifested by a much 
longer post-shock latency time (+349 %, p=0.001) compared to the galactose-untreated STZ 
rats (Fig 1c).  
To summarise, chronic oral galactose treatment had no effect on the spatial and fear-
motivated escape memory functions (either beneficial or detrimental ones) in the control 
vehicle-icv treated rats, but was successful in the normalisation of previously induced 
cognitive deficits in the STZ rats, in both the MWM and PA tests (p<0.05) (Fig. 1).  
4.2.Galactose and glucose concentrations in rat plasma and CSF after galactose 
treatment  
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Plasma galactose concentrations were found increased 15 min after a single galactose load 
(200 mg/kg) in the STZ pre-treated rats (galactose load performed 1 month after the STZ-icv 
injection) (Table 1). The increment was 2x higher after parenteral (+208%) than after oral 
(+111%) galactose administration in STZ rats in comparison to the CTR (p=0.0152 and 
p=0.0007, respectively) and galactose-untreated STZ rats (p=0.0152 and p=0.0009, 
respectively) (Table 1). However, after a 2-month oral galactose treatment no alterations were 
seen in the plasma galactose concentrations of the STZ rats (Table 1). 
There were no significant changes in CSF galactose levels of the STZ rats following a single 
galactose load, although a tendency for a mild increment was observed (+27% to +39%) 
(Table 1). The CSF galactose levels remained unchanged after chronic oral galactose 
treatment (Table 1). 
A very mild but statistically significant (+13%, p<0.0126) rise in glucose levels was observed 
in the STZ rats after a single oral load of 200 mg/kg dose in the plasma, and after a single 
parenteral load of the same dose in the CSF (+22%, p<0.0208) (Table 1). In contrast, chronic 
oral galactose treatment was associated with a smaller but significant decrease in glucose 
plasma concentrations both in the CTR (-26 %; p=0.0025) and STZ (-29 %; p=0.0343) rats 
compared to their galactose-untreated respective controls (Table 1). The opposite was found 
in the glucose CSF levels after chronic oral galactose administration, i.e. a mild but 
statistically significant increase (+15%, p=0.0112) in STZ+GAL group (Table 1). 
4.3. FDG uptake in the rat brain following chronic oral galactose treatment 
The glucose uptake was measured by FDG-PET scan in 2 animals per group chosen as group 
representatives based on their cognitive results. The representative images demonstrated a 
generally lower intensity of FDG uptake in the brain of the STZ rats (3 months after STZ-icv) 
compared to the CTRs (Fig. 2a). Quantification of FDG uptake (Fig. 2b) clearly follows the 
pattern of glucose metabolism presented in the brain images by showing an increment (+14%) 
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of glucose metabolism in the total brain after chronic oral galactose treatment (STZ+GAL) 
compared to the galactose-untreated STZ group (Fig. 2b). Across the brain regions, this effect 
was most pronounced in the brainstem (+32%) and hypothalamus (+29%), but was also seen 
in the amygdala (+23%), thalamus (+21%) and, to a lesser extent, in the frontal cortex, 
hippocampus and cerebellum (Fig. 2b). Reduction in glucose metabolism in the STZ group 
compared with the CTR group was very mild (-3%) at the level of total brain due to region-
dependent differences: a reduction in the hypothalamus (-15%), cerebellum (-7%), 
hippocampus (-6%) and brainstem, but a slight increment in the frontal cortex (+7%) and no 
change in the parietal and temporal cortices (Fig. 2b). In the CTR rats chronic oral galactose 
treatment induced no changes in glucose metabolism at the level of total brain, but some 
region-specific differences were observed in this group as well: an increment in the thalamus 
(+17%) and, to a lesser extent (+6%), in the amygdala, hippocampus and temporal cortex, 
with no changes in other regions (Fig. 2b). 
4.4. Insulin concentrations in plasma and CSF after galactose treatment 
The decrease in plasma insulin concentrations found in the STZ rats measured 1 month after 
icv treatment (-45.2 %, p=0.0092) was normalised to the control level by a single galactose 
dose of 200 mg/kg given either orally or parenterally (Fig. 3a). Although insulin levels were 
higher after an oral (+161%) than after a parenteral (+96.5%) bolus dose compared to the STZ 
rats, the difference between the groups did not reach statistical significance (p=0.24) (Fig. 
3a). No significant changes in CSF insulin levels were observed after administration of a 
single galactose dose (Fig. 3a), and neither after chronic oral galactose treatment in both 
plasma and CSF of the STZ rats (Fig 3b). 
4.5. GLP-1 levels in plasma and CSF after galactose treatment 
Both total and active GLP-1 levels were measured in the plasma, while due to an 
unmeasurably low level of its active form, it was only possible to measure total GLP-1 in the 
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CSF after single or chronic galactose treatments (Fig. 4). The most marked change was found 
in the plasma concentration of active GLP-1 both after a single dose and following chronic 
oral galactose treatment (Fig. 4, grey-coloured area). No change was found between the 
galactose-untreated STZ and CTR groups, but a single galactose dose induced a huge increase 
in active GLP-1 levels in the STZ-icv rats only after an oral bolus dose (5-fold change) but 
not after a parenteral one, compared to the CTR group (p<0.05) (Fig. 4a). However, due to 
high intragroup (STZ+200 po GAL) variability, this difference did not reach the significance 
level, although it was nearly significant compared to the STZ (3.8-fold increment; p=0.09) 
and STZ+200 ip GAL (2.9-fold increment; p=0.07) groups (Fig. 4a). Although no significant 
changes in total GLP-1 levels were found in the plasma of the STZ-icv rats after a single 
galactose load, a 78%-rise was found following the oral bolus with a nearly significant 
difference (p=0.08) compared to the STZ group (Fig. 4a). The CSF levels of total GLP-1 
were found unchanged after a single galactose dose in all groups (Fig. 4a). 
In contrast to the unchanged plasma levels of active GLP-1 in the STZ rats compared to the 
respective CTR group that were recorded 1 month after icv drug treatment (Fig. 4a), 3 months 
after STZ-icv treatment these levels were found significantly decreased (-51.2%, p=0.0045) 
(Fig. 4b). Chronic oral galactose treatment increased active GLP-1 concentrations in the 
plasma of the STZ rats (+70.2%, p=0.0275 vs STZ group), close to the levels in the CTR 
group (p=0.21 vs CTR) (Fig. 4b).  
The plasma levels of total GLP-1 were unchanged in the STZ group measured either 1 (Fig. 
4a) or 3 (Fig. 4b) months after icv treatment in comparison to the respective CTR groups. 
Oral galactose treatment demonstrated a tendency to increase total GLP-1 levels in the plasma 
of the STZ-rats both after a single dose (+78.5%, p=0.08 vs STZ) and after chronic treatment 
(+58.5%, p=0.06 vs CTR+GAL) (Fig. 4a, b). No changes in total GLP-1 levels were found in 
the CSF of the STZ-icv rats 3 months after icv treatment, regardless of the galactose treatment 
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(Fig. 4b). However, decreased total GLP-1 levels in the CSF (-30.7%; p=0.01) were found in 
the galactose-treated CTRs in comparison to the untreated CTR group (Fig. 4b), which was 
also accompanied by decreased levels of active GLP-1 in the plasma of the galactose-treated 
CTRs (-79.6%, p=0.0008 vs CTR) (Fig 4b). 
4.6. GLP-1R expression in the brain of galactose-treated rats  
We wanted to find out whether the increment in active plasma GLP-1 affected the expression 
of the GLP-1 receptor (GLP-1R) in the hippocampus, dissected out as a region of interest 
related to memory functions. As demonstrated by Western blot analysis, no significant 
changes were observed in the GLP-1R expression in the hippocampus after single oral and 
parenteral galactose doses administered to the STZ rats (Fig. 5a). No changes in the 
hippocampal expression of GLP-1R were observed either 1 (Fig. 5a) or 3 (Fig. 5b) months 
after STZ-icv administration compared to their respective controls. However, in the STZ rats 
chronic oral galactose treatment induced a huge rise in hippocampal GLP-1R expression (up 
to +80%, p=0.0022 vs all other treatments), while no effects were seen in the chronically 
galactose-treated CTR group (Fig. 5b). 
Considering the pronounced increase in FDG uptake/glucose metabolism found in the 
hypothalamus after chronic oral galactose treatment of the STZ rats compared to the untreated 
STZ group (Fig. 2b), we wanted to verify if the GLP-1R expression was also affected in this 
region. Since only the hippocampal tissue was dissected out in accordance with the 
determined protocol, and the total brain was resected from four animals for histological 
analysis, GLP-1R expression in the hypothalamus was further explored at the histological 
level (Fig. 6). Immunofluorescence staining revealed a positive red signal in the 
hypothalamus which was more intense and extensive after chronic oral galactose treatment 
both in the CTR and STZ rats, indicating increased oral galactose-induced expression of GLP-
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1R in this region (Fig. 6). No changes in GLP-1R immunofluorescence staining were 
observed between the galactose-untreated CTR and STZ rats, respectively. 
5. DISCUSSION 
The results presented here clearly show that a 2-month oral galactose treatment in doses of 
200 mg/kg normalised cognitive deficits in a STZ-icv rat model of sAD (Fig. 1). This new 
evidence strongly supports our recent finding that a 1-month oral galactose treatment 
successfully prevented the development of cognitive deficits in the same model when initiated 
on the day of the STZ-icv injection [36].  
D-galactose is a C-4 epimer of D-glucose normally found only in very small quantities in 
eukaryotic systems. At high levels, which can be induced by exogenous galactose load or 
endogenously due to its dysfunctional metabolism, galactose reacts with the free amines of 
amino acids in proteins and peptides and consequently forms advanced glycation end products 
which cause oxidative damage in the body [67]. Chronic exposure of mice or rats to 
parenteral galactose has been widely used as a model for age-related development of brain 
oxidative stress and cognitive impairment [68–73]. At first glance, these parenteral galactose-
induced effects might seem contradictory to the findings presented in this study. However, a 
major difference in the route of galactose administration between these studies and our 
research (parenteral versus oral) may provide a plausible explanation for the observed 
opposite effects of chronic galactose treatment on cognition in animals. There are several 
factors along the path of ingested galactose which differ from those induced by its parenteral 
administration, and thus might account for the beneficial effects induced by oral galactose 
administration. According to the results presented, it could be speculated that oral galactose 
may have direct and indirect effects (Fig. 7). 
20 
 
Direct effect. After ingestion, most of the galactose absorbed in circulation from the gut is 
cleared by the liver, but the remaining small quantities reach other organs, including the brain, 
and may thus directly act on the brain cells (Fig. 7). Literature data indicate that the transport 
of galactose into neurons is mediated by the insulin-independent glucose transporter GLUT3 
[39, 40], whose density is reduced in the brain of sAD patients [74, 75]. Our preliminary 
research has shown that 1-month oral galactose treatment prevents reduction in the expression 
of GLUT3 in the hippocampus of STZ-icv rats [36]. Following the intracellular uptake, which 
occurs in a concentration-dependent manner [76], galactose is quickly metabolised to glucose 
via the Leloir pathway [77]. Recent data indicate that the capacity of the brain to take up and 
metabolise galactose is similar to that of the liver [78], suggesting that under pathological 
conditions with a decreased intracellular glucose level/metabolism (like in sAD) galactose 
may serve as an alternative source of glucose/energy within the neurons. Considering the co-
localisation of GLUT3 and insulin-dependent GLUT4 found in neurons of the rat cerebral 
cortex and hippocampus [79], continuous exposure to galactose could compensate for GLUT4 
dysfunction in the insulin-resistant brain state in AD condition [80] and thus improve glucose 
hypometabolism in the brain, supported by our results of the FDG-PET scan analysis (Fig. 3).  
Our additional analysis of hippocampal GLUT3 density in the same animals whose cognitive 
results have been presented here provides evidence for a pronounced effect of oral galactose 
on GLUT3, which might be its primary target in STZ-icv-treated rats, whereas the less 
affected GLUT4 might be involved in the compensatory response (Suppl 2). At this stage of 
STZ-icv-induced pathology [32], when the first signs of early neurofibrillary changes and 
intraneuronal accumulation of Aß1-42 are just becoming manifested in the parietotemporal 
cortical region, hippocampal metabolic parameters seem to be more affected by oral galactose 
treatment in the STZ-icv rat model of sAD (Suppl 2) than the advanced AD-stage hallmarks. 
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Galactose can reach the brain via circulation after both oral and parenteral administration, but 
considering the harmful effects of high galactose concentrations [81] and due to the high 
hepatic clearance, such amounts would be much lower after oral galactose administration 
[82]. This has been clearly demonstrated by our results of galactose levels following the 
administration of oral and parenteral bolus doses of 200 mg/kg to STZ-icv rats (Table 1). 
Since this dose is generally within the range of parenteral doses used by others to generate 
neurodegeneration and aging models in mice and rats [70–73], the effects on cognition are 
likely to differ significantly between our and their results. Moreover, the results of others 
indicate that the harmful effects of parenteral galactose on cognition in healthy rats may 
sometimes be lacking, depending on other factors [83],[84]. 
Indirect effects. Galactose may also act in a paracrine fashion in the gut and, in contrast to its 
parenteral administration, strongly stimulate adjacent endocrine L-cells to secrete GLP-1 [85, 
86] [87] (Fig. 7). Intestinal L-cells have direct contact with orally given nutrients at their 
luminal surface, and with vascular tissue and parenterally given compounds through their 
basolateral surface [88]. Different structures/signaling mechanisms and their regulations are 
present at the enterocyte luminal and basolateral membranes, respectively, which could also 
account for different responses following oral and parenteral galactose treatment. Intestinally- 
derived (and, to a smaller extent, pancreatic alpha-cell-derived) GLP-1 acts as an incretin 
which dose-dependently promotes insulin secretion from the pancreatic beta cells [89]. In line 
with GLP-1-induced stimulation of insulin, in our experiments the single galactose doses 
demonstrated a potential to normalise the decrease in blood insulin levels seen transiently 1 
month after STZ-icv treatment, with no effect on normal insulin homeostasis observed in the 
chronic experiment. This finding may allow the speculation that galactose-induced insulin 
increase contributes to the beneficial effects of oral galactose only when plasma insulin levels 
are altered. 
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GLP-1 released from L-cells is extremely rapidly metabolised and inactivated by dipeptidyl 
peptidase IV (DPP-IV) [90], an enzyme expressed in enterocytes and endothelial cells [91] 
(but also in the hypothalamus, hippocampus, circumventricular organs and choroid plexus 
[88]), so that only <25% of newly secreted GLP-1 seems to leave the gut in its active form 
[89]. In our experiments, oral (but not parenteral) administration of a single galactose dose 
(200 mg/kg) induced an increment (+500%) in active GLP-1 blood levels only in the STZ-icv 
and not in the control rats (Fig. 5). In the galactose-untreated STZ-icv rats active GLP-1 
plasma levels were unchanged after 1 month, but were significantly decreased 3 months after 
STZ-icv injection, indicating a possible increment in GLP-1 degradation in the course of 
STZ-icv-induced pathology progression (Fig. 5). These results are in line with literature data 
on the long-term inhibition of DPP-IV in Alzheimer-prone mice [92], as well as on the 
therapeutic effects of DPP-IV inhibitors on cognitive impairment and brain mitochondrial 
dysfunction in insulin-resistant rats [93] and in diabetic patients with or without AD [94]. 
However, in the absence of pathology, long-term oral galactose load might have different, 
possibly undesirable effects on active GLP-1 in plasma, seen in our study as a decrease of 
active GLP-1 plasma levels in the galactose-treated control rats.  
Intestinally produced GLP-1 and its active remnant in the circulation can gain access to the 
brain nuclei after simple diffusion across the blood-brain barrier [95] but also at sites lacking 
this barrier and thus exerting a direct activation of certain neurons [96]. Alternatively, 
intestinally released GLP-1 may bind to and activate sensory afferents of the vagus nerve. In 
turn, the vagus may activate neurons of the solitary tract nucleus with a widespread projection 
pattern in the brainstem, hypothalamus and forebrain [97], which consequently may also 
produce GLP-1 themselves [97, 98]. Memory improvement in STZ-icv rats treated orally with 
galactose for 2 months accompanied by normalised plasma levels of active GLP-1 and an 
increased expression of GLP-1R in the hippocampus is in line with literature data on the 
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enhancement of associative and spatial learning in mice following increments in GLP-1R 
expression in the hippocampus, as well as following intracerebroventricular GLP-1 
administration abolished by pretreatment with a GLP-1 antagonist [99].  
The level of active GLP-1 was below the detectable limit in our experiments on Wistar rats, 
although detectable amounts of active GLP-1 in the CSF were reported in Sprague-Dawley 
rats [100]. GLP-1 in the CSF could be of gut origin or/and produced in the nucleus of the 
solitary tract and released into the CSF [101], [102], [103], but the relative contribution of 
peripherally- versus centrally-derived GLP-1 in affecting the brain functions is still unclear.  
Another brain region that may be significantly affected by GLP-1 is the hypothalamus [89], 
which has a widespread distribution of GLP-1R [98]. GLP-1R in the hypothalamus has been 
proposed to be involved in neuroendocrine responses and the regulation of energy balance 
[104]. Not only does the hypothalamic projection regulated by metabolic hormones affect 
hippocampal activity, but the same is true in vice versa order [105]. Our results demonstrate 
that chronic oral galactose treatment induces a marked increment in hypothalamic GLP-1R 
expression. Considering that sAD is accompanied by a central glucose hypometabolism and 
insulin resistance [8], our recent data on the STZ-icv induced alteration of hypothalamic 
GLUT2 and insulin receptor expression [25], as well as the here detected galactose-induced 
increment in glucose metabolism in the hypothalamus and brainstem, suggest that chronic oral 
galactose treatment might also improve the hypothalamic metabolic dysfunction.  
To summarise, various factors might affect the direction in which chronic oral galactose-
induced effects will be manifested, depending on: (i) galactose dose, since diet highly rich 
(<30%) in galactose induced hypergalactosemia and symptoms of diabetes (in contrast to the 
beneficial effects of 15%-dry matter galactose) in rats [106]; (ii) duration of oral galactose 
treatment, in line with literature data suggesting that the beneficial effects could be nullified 
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or turned to harmful in a long-term treatment [107]; (iii) the presence of pathological 
condition and its stage, since effects of oral galactose could be manifested as beneficial only 
within a particular pathological background, as seen here in the STZ-icv rat model of early- 
stage sAD [32] or reported in patients with multiple sclerosis [108] and congenital 
prosopagnosia [109]. 
6. CONCLUSIONS 
A two-month oral galactose treatment (200 mg/kg/day) normalised previously developed 
cognitive deficits in a STZ-icv rat model of early-stage sAD, associated with a galactose-
induced improvement in the brain glucose metabolism (direct effect) and stimulation of GLP-
1-mediated effects (indirect effects) by increments in plasma levels of active GLP-1 
accompanied by an increased expression of GLP-1R in the brain. In line with that it might be 
speculated that the therapeutic effects of oral galactose could be associated with the 
neuroprotective and neurotrophic, as well as regulatory, neuroendocrine role of GLP-1 in the 
brain [44,45]. Considering the clinical and non-clinical trials investigating GLP-1 analogues 
as new anti-AD drugs [44, 46, 110, 111] and galactose as a mediator of endogenous GLP-1-
induced effects as well as an alternative source of energy, the results presented here provide 
strong evidence of beneficial oral galactose effects and its interplay with GLP-1 in the 
reduction of cognitive deficits in a STZ-icv rat model of early sAD. Further research is 
needed to clarify the precise mechanism(s) involved, in order to possibly make way for new 
dietary-based strategies in AD treatment. 
ACKNOWLEDGEMENTS 
The authors would like to thank Professor Edna Grünblatt for the critical reading of the 
manuscript. Professor Vladimir Trkulja is thanked for his consultancy in the statistical 
analysis. Professor Werner Reutter† is respectfully remembered for his suggestions on 
25 
 
creating the experimental design and his support in continuing the research on beneficial 
effects of oral galactose. 
FUNDING 
This work was supported by the Croatian Science Foundation (Project IP-2014-09-4639). 
REFERENCES 
1. Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and 
biomarkers. Biochem. Pharmacol. 2014;88:640–51.  
2. De Felice FG, Lourenco M V., Ferreira ST. How does brain insulin resistance develop in 
Alzheimer’s disease? Alzheimer’s Dement. 2014;10.  
3. De La Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. 
Biochem. Pharmacol. 2014;88:548–59.  
4. Chen Y, Deng Y, Zhang B, Gong CX. Deregulation of brain insulin signaling in 
Alzheimer’s disease. Neurosci. Bull. 2014;30:282–94.  
5. Osmanovic Barilar J, Knezovic A, Grünblatt E, Riederer P, Salkovic-Petrisic M. Nine-
month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat 
model of sporadic Alzheimer’s disease. J. Neural Transm. 2015;122:565–76.  
6. Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur. J. Pharmacol. 
2013;719:170–9.  
7. Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Tariot PN, Reiman EM, et al. 
Ushering in the study and treatment of preclinical Alzheimer disease. Nat. Publ. Gr. 
2013;9:371–81.  
26 
 
8. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and 
Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal 
adults with prediabetes or early type 2 diabetes. Arch. Neurol. 2011;68:51–7.  
9. Burns CM, Chen K, Kaszniak AW, Lee W, Alexander GE, Bandy D, et al. Higher serum 
glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology. 
2013;80:1557–64.  
10. Langbaum JBS, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and 
correlational analyses of baseline fluorodeoxyglucose positron emission tomography images 
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neuroimage. 2009;45:1107–
16.  
11. Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC, Chavoix C. Neocortical and 
hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and 
perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer’s 
disease. Brain. 1999;122:1519–31.  
12. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism. Relevance to 
functional brain imaging and to neurodegenerative disorders. Ann. N. Y. Acad. Sci. 
1996;777:380–7.  
13. Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic 
Alzheimer-like pathology: An experimental approach. J. Neural Transm. Suppl. 2007;217–33.  
14. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P. Alzheimer-like changes in 
protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after 
damage to the insulin signalling pathway. J. Neurochem. 2006;96:1005–15.  
27 
 
15. Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system 
dysfunction in streptozotocin intracerebroventricularly treated rats generates 
hyperphosphorylated tau protein. J. Neurochem. 2007;101:757–70.  
16. Agrawal R, Tyagi E, Shukla R, Nath C. Insulin receptor signaling in rat hippocampus: A 
study in STZ (ICV) induced memory deficit model. Eur. Neuropsychopharmacol. 
2011;21:261–73.  
17. Chen Y, Liang Z, Tian Z, Blanchard J, Dai CL, Chalbot S, et al. Intracerebroventricular 
streptozotocin exacerbates alzheimer-like changes of 3xTg-AD mice. Mol. Neurobiol. 
2014;49:547–62.  
18. Yeo HG, Lee Y, Jeon CY, Jeong KJ, Jin YB, Kang P, et al. Characterization of Cerebral 
Damage in a Monkey Model of Alzheimer’s Disease Induced by Intracerebroventricular 
Injection of Streptozotocin. J. Alzheimer’s Dis. 2015;46:989–1005.  
19. Lee Y, Kim YH, Park SJ, Huh JW, Kim SH, Kim SU, et al. Insulin/IGF signaling-related 
gene expression in the Brain of a Sporadic Alzheimer’s disease monkey model induced by 
intracerebroventricular injection of streptozotocin. J. Alzheimer’s Dis. 2014;38:251–67.  
20. Blondel O, Portha B. Early appearance of in vivo insulin resistance in adult 
streptozotocin-injected rats. Diabete Metab. 1989;15:382–7.  
21. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat 
pancreas. Physiol. Res. 2001;50:537–46.  
22. Blokland A, Jolles J. Spatial learning deficit and reduced hippocampal ChAT activity in 
rats after an ICV injection of streptozotocin. Pharmacol. Biochem. Behav. 1993;44:491–4.  
23. Sharma M, Gupta YK. Intracerebroventricular injection of streptozotocin in rats produces 
28 
 
both oxidative stress in the brain and cognitive impairment. Life Sci. 2001;68:1021–9.  
24. Prickaerts J, Fahrig T, Blokland A. Cognitive performance and biochemical markers in 
septum, hippocampus and striatum of rats after an i.c.v, injection of streptozotocin: A 
correlation analysis. Behav. Brain Res. 1999;102:73–88.  
25. Knezovic A, Loncar A, Homolak J, Smailovic U, Osmanovic Barilar J, Ganoci L, et al. 
Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of 
intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer’s disease? J. Neural 
Transm. 2017;124:695–708.  
26. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-
term diminutions in learning and memory abilities and in cerebral energy metabolism in adult 
rats. Behav. Neurosci. 1998;112:1199–208.  
27. Nitsch R, Hoyer S. Local action of the diabetogenic drug, streptozotocin, on glucose and 
energy metabolism in rat brain cortex. Neurosci. Lett. 1991;128:199–202.  
28. Pathan AR, Viswanad B, Sonkusare SK, Ramarao P. Chronic administration of 
pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in 
rats. Life Sci. 2006;79:2209–16.  
29. Plaschke K, Hoyer S. Action of the diabetogenic drug streptozotocin on glycolytic and 
glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int. J. Dev. Neurosci. 
1993;11:477–83.  
30. Saxena G, Singh SP, Agrawal R, Nath C. Effect of donepezil and tacrine on oxidative 
stress in intracerebral streptozotocin-induced model of dementia in mice. Eur. J. Pharmacol. 
2008;581:283–9.  
29 
 
31. Salkovic-Petrisic M, Osmanovic-Barilar J, Brückner MK, Hoyer S, Arendt T, Riederer P. 
Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a 
long-term follow up study. J. Neural Transm. 2011;118:765–72.  
32. Knezovic A, Osmanovic-Barilar J, Curlin M, Hof PR, Simic G, Riederer P, et al. Staging 
of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-
induced rat model of Alzheimer’s disease. J. Neural Transm. 2015;122:577–92.  
33. Salkovic-Petrisic M, Knezovic A, Hoyer S, Riederer P. What have we learned from the 
streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic 
strategies in Alzheimer’s research. J. Neural Transm. 2013;120:233–52.  
34. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer’s disease: 
clinical trials and drug development. Lancet Neurol. 2010;9:702–16.  
35. Misra S, Medhi B. Drug development status for Alzheimer’s disease: Present scenario. 
Neurol. Sci. 2013;34:831–9.  
36. Salkovic-Petrisic M, Osmanovic-Barilar J, Knezovic A, Hoyer S, Mosetter K, Reutter W. 
Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated 
intracerebroventricularly with streptozotocin. Neuropharmacology. Elsevier Ltd; 2014;77:68–
80.  
37. Frey PA. The Leloir pathway: a mechanistic imperative for three enzymes to change the 
stereochemical configuration of a single carbon in galactose. FASEB J. 1996;10:461–70.  
38. Ross KL, Davis CN, Fridovich-Keil JL. Differential roles of the Leloir pathway enzymes 
and metabolites in defining galactose sensitivity in yeast. Mol. Genet. Metab. 2004;83:103–
16.  
30 
 
39. Gould GW, Thomas HM, Jess TJ, Bell GI. Expression of human glucose transporters in 
Xenopus oocytes: kinetic characterization and substrate specificities of the erythrocyte, liver, 
and brain isoforms. Biochemistry. 1991;30:5139–45.  
40. Seatter MJ, Kane S, Porter LM, Arbuckle MI, Melvin DR, Gould GW. Structure-function 
studies of the brain-type glucose transporter, GLUT3: Alanine-scanning mutagenesis of 
putative transmembrane helix VIII and an investigation of the role of proline residues in 
transport catalysis. Biochemistry. 1997;36:6401–7.  
41. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 
2007;132:2131–57.  
42. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor 
pathways for intervention in Alzheimer’s disease. Curr Alzheimer Res. 2005;2:377–85.  
43. Sandoval D a, D’Alessio D a. Physiology of Proglucagon Peptides: Role of Glucagon and 
GLP-1 in Health and Disease. Physiol. Rev. 2015;95:513–48.  
44. Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, et al. Crosstalk 
between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against 
neurodegeneration. Biochim. Biophys. Acta - Mol. Basis Dis. 2013;1832:527–41.  
45. Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of 
glucagon-like peptide-1: An emerging opportunity to treat neurodegenerative and 
cerebrovascular disorders. Br. J. Pharmacol. 2012;166:1586–99.  
46. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, 
cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.  
47. Li L, Zhang ZF, Holscher C, Gao C, Jiang YH, Liu YZ. (Val 8) glucagon-like peptide-1 
31 
 
prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular 
damage induced by streptozotocin in rat brains. Eur. J. Pharmacol. 2012;674:280–6.  
48. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like 
peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. 
FEBS Lett. 1995;358:219–24.  
49. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 Binding Sites in the 
Rat Brain: Evidence that Exendin-4 is a Ligand of Brain GLP-1 Binding Sites. Eur. J. 
Neurosci. 1995;7:2294–300.  
50. Noble EP, Wurtman RJ, Axelrod J. A simple and rapid method for injecting H3-
norepinephrine into the lateral ventricle of the rat brain. Life Sci. 1967;6:281–91.  
51. Salkovic-Petrisic M, Knezovic A, Osmanovic-Barilar J, Smailovic U, Trkulja V, Riederer 
P, et al. Multi-target iron-chelators improve memory loss in a rat model of sporadic 
Alzheimer’s disease. Life Sci. Elsevier Inc.; 2015;136:108–19.  
52. Kliegman RM, Morton S. Sequential intrahepatic metabolic effects of enteric galactose 
alimentation in newborn rats. Pediatr. Res. 1988;24:302–7.  
53. Vorhees C V, Williams MT. Morris water maze: procedures for assessing spatial and 
related forms of learning and memory. Nat. Protoc. 2006;1:848–58.  
54. Morris RGM. Spatial localization does not require the presence of local cues. Learn. 
Motiv. 1981;12:239–60.  
55. Walters GC, Abel EL. Passive avoidance learning in rats, mice, gerbils, and hamsters. 
Psychon. Sci. 1971;22:269–70.  
32 
 
56. Sempere Roldan P, Chereul E, Dietzel O, Magnier L, Pautrot C, Rbah L, et al. Raytest 
ClearPET(TM), a new generation small animal PET scanner. Nucl. Instruments Methods 
Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip. 2007;571:498–501.  
57. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin 
phenol reagent. J. Biol. Chem. 1951;193:265–75.  
58. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a 
non-carcinogenic chromogen. J. Clin. Pathol. 1969;22:158–61.  
59. Barnard ND, Bush AI, Ceccarelli A, Cooper J, de Jager CA, Erickson KI, et al. Dietary 
and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol. Aging. 
2014;35:74–8.  
60. Cooper JK. Nutrition and the brain: What advice should we give? Neurobiol. Aging. 
2014;35:79–83.  
61. Weinreb O, Amit T, Bar-Am O, Youdim MBH. Neuroprotective effects of multifaceted 
hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer’s 
disease. Br. J. Pharmacol. 2016;173:2080–94.  
62. Flatt PR, Kwasowski P, Bailey CJ. Stimulation of gastric inhibitory polypeptide release in 
ob/ob mice by oral administration of sugars and their analogues. J. Nutr. 1989;119:1300–3.  
63. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold 
promise as a novel treatment strategy for Alzheimer’s disease. Recent Pat. CNS Drug Discov. 
2010;5:109–17.  
64. Faivre E, Hölscher C. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in 
aged wild type mice and in an Alzheimer’s disease mouse model. J. Alzheimers. Dis. 
33 
 
2013;35:267–83.  
65. Duffy AM, Hölscher C. The incretin analogue D-Ala2GIP reduces plaque load, 
astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease. 
Neuroscience. 2013;228:294–300.  
66. Shi L, Zhang Z, Li L, Hölscher C. A novel dual GLP-1/GIP receptor agonist alleviates 
cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. 
Behav. Brain Res. 2017;327:65–74.  
67. Zhang XL, Jiang B, Li ZB, Hao S, An LJ. Catalpol ameliorates cognition deficits and 
attenuates oxidative damage in the brain of senescent mice induced by d-galactose. 
Pharmacol. Biochem. Behav. 2007;88:64–72.  
68. Budni J, Pacheco R, da Silva S, Garcez ML, Mina F, Bellettini-Santos T, et al. Oral 
administration of D-galactose induces cognitive impairments and oxidative damage in rats. 
Behav. Brain Res. 2016;302:35–43.  
69. Ho SC, Liu JH, Wu RY. Establishment of the mimetic aging effect in mice caused by D-
galactose. Biogerontology. 2003;4:15–8.  
70. Wei H, Li L, Song Q, Ai H, Chu J, Li W. Behavioural study of the D-galactose induced 
aging model in C57BL/6J mice. Behav. Brain Res. 2005;157:245–51.  
71. Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, et al. Chronic systemic D-galactose exposure 
induces memory loss, neurodegeneration, and oxidative damage in mice: Protective effects of 
R-α-lipoic acid. J. Neurosci. Res. 2006;84:647–54.  
72. Kumar A, Prakash A, Dogra S. Centella asiatica Attenuates D-Galactose-Induced 
Cognitive Impairment, Oxidative and Mitochondrial Dysfunction in Mice. Int. J. Alzheimers. 
34 
 
Dis. 2011;2011:347569.  
73. Wang W, Li S, Dong H ping, Lv S, Tang Y yuan. Differential impairment of spatial and 
nonspatial cognition in a mouse model of brain aging. Life Sci. 2009;85:127–35.  
74. Kalaria RHN, Harik SI. Reduced Glucose Transporter at the Blood‐Brain Barrier and in 
Cerebral Cortex in Alzheimer Disease. J. Neurochem. 1989;53:1083–8.  
75. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations 
of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s 
disease. Ann. Neurol. 1994;35:546–51.  
76. Mueckler M. Facilitative glucose transporters. Eur. J. Biochem. 1994;219:713–25.  
77. Cohn RM, Segal S. Galactose metabolism and its regulation. Metabolism. 1973;22:627–
42.  
78. Roser M, Josic D, Kontou M, Mosetter K, Maurer P, Reutter W. Metabolism of galactose 
in the brain and liver of rats and its conversion into glutamate and other amino acids. J. Neural 
Transm. 2009;116:131–9.  
79. Apelt J, Mehlhorn G, Schliebs R. Insulin-sensitive GLUT4 glucose transporters are 
colocalized with GLUT3- expressing cells and demonstrate a chemically distinct neuron-
specific localization in rat brain. J. Neurosci. Res. 1999;57:693–705.  
80. Pearson-Leary J ME. Intrahippocampal administration of amyloid-β(1-42) oligomers 
acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism. J. 
Alzheimer’s Dis. 2012;30:413–22.  
81. Chiu C-S, Chiu Y-J, Wu L-Y, Lu T-C, Huang T-H, Hsieh M-T, et al. Diosgenin 
35 
 
ameliorates cognition deficit and attenuates oxidative damage in senescent mice induced by 
D-galactose. Am. J. Chin. Med. 2011;39:551–63.  
82. Henderson JM, Kutner MH, Bain RP. First-order clearance of plasma galactose: the effect 
of liver disease. Gastroenterology. 1982;83:1090–6.  
83. Cardoso A, Magano S, Marrana F, Andrade JP. D-Galactose High-Dose Administration 
Failed to Induce Accelerated Aging Changes in Neurogenesis, Anxiety, and Spatial Memory 
on Young Male Wistar Rats. Rejuvenation Res. 2015;18:497–507.  
84. Hao L, Huang H, Gao J, Marshall C, Chen Y, Xiao M. The influence of gender, age and 
treatment time on brain oxidative stress and memory impairment induced by D-galactose in 
mice. Neurosci. Lett. 2014;571:45–9.  
85. Ritzel U, Fromme A, Ottleben M, Leonhardt U, Ramadori G. Release of glucagon-like 
peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum. Acta Diabetol. 1997;34:18–21.  
86. Shima K, Suda T, Nishimoto K, Yoshimoto S. Relationship between molecular structures 
of sugars and their ability to stimulate the release of glucagon-like peptide-1 from canine ileal 
loops. Acta Endocrinol. (Copenh). 1990;123:464–70.  
87. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like 
peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to 
nutrients. Digestion. 1995;56:117–26.  
88. Candeias EM, Sebastião IC, Cardoso SM, Correia SC, Carvalho CI, Plácido AI, et al. Gut-
brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J. 
Diabetes. 2015;6:807–27.  
89. Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007;87:1409–39.  
36 
 
90. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of 
dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 2014;35:992–1019.  
91. Hansen L, Deacon C, Ørskov C, Holst J. Glucagon-like peptide-1-(7–36) amide is 
transformed to glucagon-like peptide-1-(9–36) amide by dipeptidyl peptidase IV in the 
capillaries supplying the L cells of the. Endocrinology. 1999;140:5356–63.  
92. D’Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F, et al. 
Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice. Exp. Gerontol. 
2010;45:202–7.  
93. Pintana H, Apaijai N, Chattipakorn N, Chattipakorn SC. DPP-4 inhibitors improve 
cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol. 
2013;218:1–11.  
94. Isik AT, Soysal P, Yay A, Usarel C. The effects of sitagliptin, a DPP-4 inhibitor, on 
cognitive functions in elderly diabetic patients with or without Alzheimer’s disease. Diabetes 
Res. Clin. Pract. 2017;123:192–8.  
95. Kastin AJ, Akerstrom V, Pan W. Interactions of Glucagon-Like Peptide-1 (GLP-1) with 
the Blood-Brain Barrier. J. Mol. Neurosci. 2002;18:7–14.  
96. Alvarez E, Martínez MD, Roncero I, Chowen JA, García-Cuartero B, Gispert JD, et al. 
The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose 
metabolism in the human hypothalamus and brainstem. J. Neurochem. 2005;92:798–806.  
97. Jin SLC, Han VKM, Simmons JG, Towle AC, Lauder JM, Lund PK. Distribution of 
glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: An 
immunocytochemical study. J. Comp. Neurol. 1988;271:519–32.  
37 
 
98. Renner E, Puskás N, Dobolyi A, Palkovits M. Glucagon-like peptide-1 of brainstem origin 
activates dorsomedial hypothalamic neurons in satiated rats. Peptides. 2012;35:14–22.  
99. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like 
peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173–9.  
100. Hsu TM, Hahn JD, Konanur VR, Lam A, Kanoski SE. Hippocampal GLP-1 Receptors 
Influence Food Intake, Meal Size, and Effort-Based Responding for Food through Volume 
Transmission. Neuropsychopharmacology. 2014;40:327–37.  
101. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary 
tract project directly to the ventral tegmental area and nucleus accumbens to control for food 
intake. Endocrinology. 2012;153:647–58.  
102. Gu G, Roland B, Tomaselli K, Dolman CS, Lowe C, Heilig JS. Glucagon-like peptide-1 
in the rat brain: distribution of expression and functional implication. J Comp Neurol. 
2013;521:2235–61.  
103. Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and 
characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol. 
Metab. 2015;4:718–31.  
104. Schick RR, Zimmermann JP, vorm Walde T, Schusdziarra V. Peptides that regulate food 
intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to 
suppress feeding in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003;284:R1427–35.  
105. Davidson TL, Kanoski SE, Schier LA, Clegg DJ, Benoit SC. A potential role for the 
hippocampus in energy intake and body weight regulation. Curr. Opin. Pharmacol. 
2007;7:613–6.  
38 
 
106. Niewoehner CB, Neil B. Mechanism of delayed hepatic glycogen synthesis after an oral 
galactose load vs. an oral glucose load in adult rats. Am J Physiol. 1992;263:E42-9.  
107. Bharti Chogtu , A. Avinash , Sushil Kiran Kunder, Amod Tilak RS. Evaluation of acute 
and chronic effects of D-galactose on memory and learning in Wistar rats. Clin. 
Psychopharmacol. Neurosci. 2017;E- ahe.  
108. Panfoli I, Ravera S, Calzia D, Santi C. Missed evolution of demyelinizing brain lesions 
durinr supplementation with natural compounds : A Case Report. Med. Res. Arch. 2016;4:1–
12.  
109. Esins J, Schultz J, Bülthoff I, Kennerknecht I. Galactose uncovers face recognition and 
mental images in congenital prosopagnosia: the first case report. Nutr. Neurosci. 
2014;17:239–40.  
110. Talbot K. Brain insulin resistance in Alzheimer’s disease and its potential treatment with 
GLP-1 analogs. Neurodegener. Dis. Manag. 2014;4:31–40.  
111. Perry TA, Greig NH. A new Alzheimer’s disease interventive strategy: GLP-1. Curr. 
Drug Targets. 2004;5:565–71.  
 
39 
 
Table 1. Galactose and glucose concentrations in plasma and cerebrospinal fluid of 
streptozotocin-intracerebroventricularly treated rats measured following a single dose 
and chronic galactose treatment 
 
 
GLUCOSE 
CONCENTRATION ± %SEM  
(% above or below the 
respective control)  
GALACTOSE CONCENTRATION± 
%SEM  
(% above or below the respective 
control) 
PLASMA CSF PLASMA CSF 
Measured 15 minutes after a single galactose dose  
STZ 
+3%±5.13  
(N=10) 
+10%±8.06  
(N=9) 
+3%±24.48  
(N=9) 
-2%±23.28  
(N=9) 
STZ + single 200 
po GAL 
 13%±3.32
a  
(N=10) 
+10%±6.38  
(N=7) 
  +111%±12.60
a,b  
(N=9) 
+39%±25.59  
(N=8) 
STZ + single 200 ip 
GAL 
+7%±2.96  
(N=9) 
  +22%±3.62
a  
(N=8) 
   +208%±3.10
a,b,c  
(N=9) 
+27%±30.47  
(N=9) 
Measured after 2 months of oral galactose treatment  
STZ 
-5%±8.10  
(N=10) 
+4%±2.53  
(N=10) 
+2%±11.68  
(N=10) 
-8%±17.77  
(N=10) 
CTR + chronic 200 
po GAL 
 -26%±5.36
a  
(N=10) 
+8%±3.49  
(N=10) 
-4%±6.70 
(N=10) 
-28%±15.51  
(N=8) 
STZ + chronic 200 
po GAL 
  -29%±8.63a,b  
(N=10) 
 +15%±3.44
a,b  
(N=8) 
 -16%±5.35
  
(N=10) 
-31%±19.48  
(N=7) 
CSF, cerebrospinal fluid; GAL, galactose, CTR, control rats; STZ, rats treated intracerebroventricularly with streptozotocin (3 
mg/kg); STZ + single 200 po GAL, rats treated orally (gastric tube) with a single galactose dose (200 mg/kg) given 1 month after 
STZ; STZ + 200 ip GAL, rats treated intraperitoneally with a single galactose dose (200 mg/kg) given 1 month after STZ; 
CTR/STZ + chronic 200 po GAL, rats treated 2 months  with galactose (200 mg/kg/day in drinking water); %SEM, percent of 
standard error of mean; ap<0.05 vs respective control; bp<0.05 vs STZ;  cp<0.05 vs STZ + 200 po GAL. N - number of animals 
per group (N=10 for CTR groups in both experiments) 
 
 
FIGURE TITLES AND LEGENDS 
Figure 1. Oral galactose treatment normalises cognitive deficits induced by 
intracerebroventricular administration of streptozotocin. Animals were euthanised 3 
months after  intracerebroventricular (icv) treatment with streptozotocin (STZ-icv) (3 mg/kg) 
or vehicle (CTR). Oral galactose treatment (200 mg/kg/day in a drink ad libitum) started 1 
month after the STZ-icv injection and lasted 2 months. Cognitive performance was measured 
at the end of galactose treatment. (a) Each dot represents a group value (time to find the 
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platform or number of mistakes) expressed as mean +/- SEM of learning trials (days 1-5) in 
Morris Water Maze (MWM) test. Statistical significance for a particular group at the 
particular time-point is expressed by different marks depending on the group used as 
comparator: * p<0.05 compared to the control (CTR); # p<0.05 compared to the STZ-icv 
group (STZ); $ p<0.05 compared to the galactose-treated controls (CTR+GAL). STZ+GAL, 
galactose-treated STZ-icv rats N=10 for CTR, STZ, CTR+GAL, N=9 for STZ+GAL. (b) 
Each bar represents mean +/- SEM of the time spent in target quadrant and number of 
mistakes in the probe trial of MWM test (day 6) (*p<0.05) N=10 per group. (c) Each bar 
represents post-shock latency time measured by Passive Avoidance (PA) test. Values are 
expressed as mean +/- SEM. N= 10 per group. Data were analysed by non-parametric 
Kruskal-Wallis one-way ANOVA test followed by a Mann Whitney U test (*p<0.05). Group 
comparisons during the learning trials were analysed by Two-way ANOVA for repeated-
measures with Bonferroni post-hoc test on ln transformed data to meet the condition of 
normality. 
Figure 2. Glucose uptake using FDG as a radiotracer in streptozotocin-treated animals 
subjected to chronic oral galactose treatment. Oral galactose treatment (200 mg/kg/day in a 
drink ad libitum) started 1 month after intracerebroventricular (icv) treatment with 
streptozotocin (STZ-icv) (3 mg/kg) or vehicle (CTR) and lasted for 2 months, after which two 
animals per group were subjected to PET scanning. (a) Representative images of one animal 
per group are presented. (b) Regions of interest were selected and analysed by PMOD 
software for indication of glucose uptake/metabolism rate. The bars represent calculated 
kBq/cc for each region and total brain. CTR, control vehicle-icv treated rats who drank tap 
water; CTR+GAL, control vehicle-icv treated rats who drank galactose for 2 months; STZ, 
STZ-icv treated rats who drank tap water; STZ+GAL, STZ-icv treated rats who drank 
galactose; CTX, cortex. 
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Figure 3. Insulin concentrations in plasma and cerebrospinal fluid after a single 
galactose dose and after chronic galactose treatment. (a) Insulin concentration in plasma 
and cerebrospinal fluid (CSF) after a single galactose bolus dose (200 mg/kg) given orally or 
intraperitoneally 1 month after intracerebroventricular streptozotocin (3mg/kg) treatment 
(STZ + 200 po GAL and STZ + 200 ip GAL, respectively). N (insulin/plasma) = 9 per group. 
N (insulin/CSF): N=9 for control (CTR) and STZ, N=7 for STZ + 200 po GAL, N=8 for STZ 
+ 200 ip GAL. (b) Insulin concentration in plasma and CSF of controls (CTR) and STZ-icv 
rats measured after 2-month oral galactose treatment (200 mg/kg/day) given as a drink ad 
libitum (CTR+GAL, STZ+GAL) initiated 1 month after STZ-icv injection. Each bar 
represents mean +/- SEM. N (insulin/plasma) =10 per group. N (insulin/CSF): N= 9 for CTR, 
N=10 for STZ, CTR+GAL, N=8 for STZ+GAL. Data were analysed by non-parametric 
Kruskal-Wallis one-way ANOVA test followed by Mann Whitney U test (*p<0.05). 
Figure 4. Glucagon-like peptide-1 concentration in plasma and cerebrospinal fluid after 
a single galactose dose and chronic galactose treatment. (a) Total glucagon-like peptide 1 
(GLP-1) concentration in plasma and cerebrospinal fluid (CSF) and active GLP-1 
concentration in plasma after a single galactose bolus dose (200 mg/kg) given orally or 
intraperitoneally 1 month after intracerebroventricular streptozotocin (3mg/kg) treatment 
(STZ + 200 po GAL and STZ + 200 ip GAL, respectively). N (GLP-1/plasma) = 8 per group, 
N (active GLP-1/plasma) = 9 per group, N (GLP-1/CSF): N= 6 for control (CTR), N=9 for 
STZ, N= 7 for STZ + 200 po GAL, STZ + 200 ip GAL.  (b) Total GLP-1 concentration in 
plasma and CSF and active GLP1 concentration in plasma of CTR and STZ-icv rats after a 2-
month galactose treatment (200 mg/kg/day) given as a drink (CTR+GAL, STZ+GAL) that 
started 1 month after STZ-icv injection. N (GLP-1/plasma=10 per group, N (GLP-1/CSF): 
N=10 for CTR, STZ, CTR+GAL, N=8 for STZ+GAL. N (active GLP-1/plasma): N= 10 for 
STZ; N= 8 for CTR, CTR+GAL; N=9 for STZ+GAL. Grey-coloured graphs represent 
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significant changes of active GLP1 concentration found in plasma.  Each bar represents mean 
+/- SEM. Data were analysed by non-parametric Kruskal-Wallis one-way ANOVA test 
followed by Mann Whitney U test (*p<0.05). 
Figure 5. Glucagon-like peptide-1 receptor expression in hippocampus after a single 
galactose dose and chronic galactose treatment. Glucagon-like peptide-1 receptor (GLP-
1R, 53 kDa) expression in the hippocampus (HPC) was measured by Western blot analysis 
with the representative blots presented beneath the graphs. Anti-β-actin (42 kDa) was used as 
a loading control. (a) GLP-1R expression in HPC after a single galactose bolus dose (200 
mg/kg) given orally or intraperitoneally 1 month after intracerebroventricular streptozotocin 
(3mg/kg) treatment (STZ + 200 po GAL and STZ + 200 ip GAL, respectively) N=6 per 
group. (b) GLP-1R expression in HPC of controls (CTR) and STZ-icv rats after a 2-month 
galactose treatment (200 mg/kg/day) given as a drink ad libitum (CTR + GAL, STZ + GAL) 
that started 1 month after STZ-icv injection N=6 per group. Values are expressed as mean +/- 
SEM and data were analysed by non-parametric Kruskal-Wallis one-way ANOVA test 
followed by Mann Whitney U test (*p<0.05). 
Figure 6. Immunofluorescence staining of glucagon-like peptide-1 receptor in rat 
hypothalamus following chronic oral galactose treatment. Animals were euthanised 3 
months after intracerebroventricular (icv) treatment with streptozotocin (STZ-icv) (3 mg/kg) 
or vehicle (CTR). Oral galactose treatment (200 mg/kg/day in a drink ad libitum) started 1 
month after STZ-icv injection and lasted for 2 months until sacrifice. Brain slices (35 µm) of 
4 rats per group were subjected to immunofluorescence staining with glucagon-like peptide-1 
receptor (GLP-1R) antibody. Representative photomicrographs show a positive GLP-1R 
signal in the medial preoptic area of the anterior hypothalamus seen as red staining. The low-
magnification image (Scale bar = 500 µm) shows the area where high-magnification 
43 
 
photomicrographs have been recorded. Cells with a positive signal are indicated by the white 
arrows. Scale bar = 50 µm 
Figure 7. Proposed mechanisms of the therapeutic effects of oral galactose treatment in 
a streptozotocin-induced rat model of sporadic Alzheimer’s disease. Daily oral intake 
(drink) of galactose (200 mg/kg) may improve cognitive deficits and elicit beneficial effects 
in the brain of a streptozotocin intracerebroventricularly-treated rat model (STZ-icv model) of 
sporadic Alzheimer’s disease (sAD) through the proposed direct and indirect effects. Direct 
effect. After ingestion and intake into/release from the gut enterocytes, galactose is absorbed 
into the circulation. A large proportion of the galactose undergoes hepatic clearance, but the 
small remnant amounts reach other organs including the brain, where galactose is taken up by 
the neurons and converted to glucose by the Leloir pathway. This may consequently increase 
intracellular glucose levels and improve previously developed glucose hypometabolism, as 
evidenced here by the FDG-PET scan images of galactose-untreated and galactose-treated 
STZ-icv rat model. Indirect effects. After being released from the gut enterocytes, galactose 
stimulates adjacent L-cells to secrete glucagon-like peptide 1 (GLP-1). Gut-born GLP-1 may 
reach the brain via circulation (active GLP-1 form) and directly stimulate the GLP-1 receptors 
in the brain, but can also additionally stimulate sensory afferents of the vagus nerve in the gut 
which project to the solitary tract nucleus with a widespread projection pattern in the 
brainstem, hypothalamus and forebrain. Upon stimulation, these nerves may also produce 
GLP-1, which can then stimulate GLP-1 receptors in the brain. Stimulation of GLP-1 
receptors has been shown in the literature to be involved in neuroprotection, neurotrophic 
effects and neurogenesis, which may account for the improved cognition observed here, as 
well as for neuroendocrine effects. The contribution of direct and/or indirect effects on the 
therapeutic potential of oral galactose in a STZ-icv rat model needs to be further elucidated. 
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SUPPLEMENT MATERIAL 1 
 
RATS’ SWIMMING VELOCITY IN THE MORRIS WATER MAZE TEST 
 
Swimming velocity of the animals during the Morris Water Maze Test was not affected 
by the treatment. During the learning trials in the Morris Water Maze (MWM) test, 
treatment accounted for 9.19% of the total variance (after adjustment for matching). The 
effect is considered not significant (p=0.12). Only the effect on the day of the treatment is 
considered significant (p<0.0001), and accounts for 7.87% of the total variance. During the 
probe trial there were no differences in the velocity between the groups (p=0.3916). Velocity 
had no effect on the measured time and mistakes during the MWM test. 
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Fig 1. Swimming velocity of the animals during the Morris Water Maze test was not affected by the 
treatments. Animals were euthanised 3 months after intracerebroventricular (icv) treatment with streptozotocin 
(STZ-icv) (3 mg/kg) or vehicle (CTR). Oral galactose treatment (200 mg/kg/day in a drink ad libitum) started 1 
month after the STZ-icv injection and lasted 2 months. Cognitive performance was measured at the end of the 
galactose treatment. Each dot represents a group value (velocity) expressed as mean +/- SEM of learning trials 
(days 1-5) in Morris Water Maze (MWM) test (a). Each bar represents mean +/- SEM of time spent in the target 
quadrant and number of mistakes in the probe trial of MWM test (day 6). (b) N=10 per group. Group 
comparisons during the learning trials were analysed by Two-way ANOVA for repeated-measures with 
Bonferroni post-hoc test on ln transformed data to meet the condition of normality. The statistical analysis for 
the probe trial was done by non-parametric Kruskal-Wallis test. 
SUPPLEMENT MATERIAL 2 
 
EXPRESSION OF GLUCOSE TRANSPORTERS, TAU PROTEIN AND AMYLOID-β 
IN THE BRAIN FOLLOWING CHRONIC ORAL GALACTOSE TREATMENT 
 
Experimental design and measurement  
The following analysis was done on tissue samples of animals from the experiment described 
in the main text. The rats were subjected to general anaesthesia (ketamine 50 mg/kg/xylazine 
5 mg/kg ip) and given streptozotocin (STZ) bilaterally into each lateral ventricle (2 
µL/ventricle) in a total dose of 3 mg/kg (dissolved in 0.05 M citrate buffer, pH 4.5, split into 
two doses on days 1 and 3), while the controls (CTR) received vehicle only. Two-month oral 
administration of galactose (GAL, 200 mg/kg/day) dissolved in tap water was given as a 
drink, while the respective controls received equal amounts of tap water for drinking in 
similar bottles. The galactose treatment was initiated one month after STZ/buffer-icv 
injection. The animals were divided into 4 groups (10 animals per group): CTR, control 
group (vehicle-icv treated); STZ, STZ-icv group; CTR+GAL, control group treated daily 
with galactose 200 mg/kg po; STZ+GAL, STZ-icv group treated daily with galactose 200 
mg/kg po. Expression of glucose transporters 3 and 4 (GLUT3, GLUT4), phosphorylated tau 
(Ser202, Thr205 / AT8) and total tau was measured by Western blot and amyloid β 1-42 was 
measured by a commercial ELISA kit in the hippocampus (HPC).  
Statistics 
Data were expressed as mean ± SEM with significance of between-group differences in all 
cognitive and biochemical analyses tested by Kruskall-Wallis one-way ANOVA analysis of 
variance, followed by Mann-Whitney U-test, with p<0.05 considered statistically significant, 
using GraphPad Prism 5 statistical software. 
Results and discussion 
Chronic oral galactose treatment which had been initiated 1 month after STZ administration, 
induced a 2-fold increment in GLUT3 expression only in the STZ group, which was 
significant compared both to the galactose-untreated STZ (p=0.0087) and the galactose-
treated control group (p=0.0087) (Fig. 1). However, this was followed by a significant 
decrease in GLUT4 expression in both galactose-treated (STZ and CTR) groups compared to 
the galactose-untreated STZ group (p=0.0152 and p=0.026, respectively). These data are in 
line with our previous observation of the significant oral galactose-induced increase in 
GLUT3 that was detected 1 month after STZ-icv treatment (Salkovic-Petrisic et al., 2014 
[36]). These results indicate that GLUT3 might be more susceptible to galactose effects than 
GLUT4. Since GLUT3 has been found significantly decreased at earlier post-STZ time-
points (e.g. 1 month in our previous report /Salkovic-Petrisic et al., 2014 [36]/) and a 
tendency of decrease is seen still here 3 months after STZ administration, it could also mean 
that the GLUT3, unlike GLUT4, might be a direct target of STZ. On the contrary, the 
tendency of increase seen here in GLUT4 expression 3 months after STZ might indicate an 
indirect compensatory response to the insulin-resistant brain state developed after STZ-icv 
treatment (Osmanovic Barilar et al., 2015 [5]), which has been diminished here after 
galactose treatment. This galactose-induced reduction in GLUT4 levels might be due to a 
possible rise in intracellular glucose levels resulting from galactose conversion to glucose 
(Roser et al., 2009 [78],) and a consequent reduced need for glucose uptake by GLUT4 
appearing at the cell membrane. Since galactose is a substrate for GLUT3 and not for 
GLUT4, it cannot be excluded that it also regulates GLUT3 expression and/or repairs damage 
induced by STZ, which is why only the STZ+GAL group demonstrated significant 
increments in GLUT3 expression. 
 
  
 
  
Figure 1. Hippocampal amyloid β1-42, glucose transporter and tau protein expression 
following chronic oral galactose treatment in a streptozotocin-induced rat model of 
sporadic Alzheimer’s disease. GLUT3, glucose transporter 3; GLUT4, glucose transporter 
4; AT8, Ser202Thr205 phosphorylated tau protein; HPC, hippocampus; icv, 
intracerebroventricular; CTR, control buffer-icv treated rats; STZ, streptozotocin-icv treated 
rats; GAL, oral galactose; CTR+GAL, control rats treated by oral galactose for 2 months; 
STZ+GAL, STZ rats treated by oral galactose for 2 months. 
 
Hippocampal AT8 expression has not shown significant alterations in the STZ group 
compared to the CTR, but galactose treatment indicated a tendency to decrease AT8 
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expression in both the STZ and CTR groups, which, however, did not reach the statistical 
significance level (Fig. 1). Since similar alterations have been observed in total tau 
expression in the galactose-treated STZ and CTR groups compared to their respective 
galactose-untreated groups, the ratio of AT8/total tau protein has been calculated. Due to a 
high intragroup variability, the difference between the groups was not statistically significant, 
although it was possible to observe a tendency of increase in the STZ vs CTR groups and its 
normalisation in the STZ+GAL vs STZ groups. AT8 targets epitopes of tau protein 
phosphorylated by Cdk5 kinase, which is not downstream the insulin receptor pathway. The 
absence of changes found in the hippocampus 3 months after STZ-icv treatment is in line 
with our previous reports of the pathology staging scheme in this model, showing signs of 
marked AT8 immunoreactivity in this region from the 6th month onward (Knezovic et al., 
2015 [32])). Considering the speculation that galactose might have beneficial effects by 
compensating for a decreased intracellular glucose level and insulin resistant brain state, the 
decrease in AT8 expression, although potentially desirable, does not seem to significantly 
depend on previous STZ-induced damage, at least not at this time-point after STZ 
administration. Further research by means of antibodies targeting other epitopes on phospho 
tau protein, possibly those phosphorylated by GSK-3ß, as well as exploring other time-points 
after STZ administration (stage of advanced pathology), is needed before a final conclusion 
on the tau protein-oral galactose correlation.   
Our preliminary analysis has shown that, similar to AT8, no significant changes have been 
found in Aß1-42 levels in the rat hippocampus 3 months following STZ-icv treatment 
(p=0.089 by Kruskall-Wallis test) (Fig. 1). This is in line with our previous findings that 
intraneuronal accumulation of Aß1-42 starts no earlier than 3 months after STZ, occurring 
first in the parietotemporal cortex (Knezovic et al., 2015 [32]). Further research of a more 
advanced pathology stage in this model might bring some more light to the correlation of oral 
galactose treatment and amyloid pathology in the STZ-icv rat model of sAD. 
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